ATE512669T1 - Verfahren zur anpassung der immunantwort an ein antigen oder immunogen - Google Patents
Verfahren zur anpassung der immunantwort an ein antigen oder immunogenInfo
- Publication number
- ATE512669T1 ATE512669T1 AT05722399T AT05722399T ATE512669T1 AT E512669 T1 ATE512669 T1 AT E512669T1 AT 05722399 T AT05722399 T AT 05722399T AT 05722399 T AT05722399 T AT 05722399T AT E512669 T1 ATE512669 T1 AT E512669T1
- Authority
- AT
- Austria
- Prior art keywords
- immunogen
- immune
- immune response
- responses
- antigen
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000028996 humoral immune response Effects 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53492304P | 2004-01-07 | 2004-01-07 | |
| PCT/US2005/000710 WO2005067966A1 (en) | 2004-01-07 | 2005-01-07 | Methods for tailoring the immune response to an antigen or immunogen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512669T1 true ATE512669T1 (de) | 2011-07-15 |
Family
ID=34794335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05722399T ATE512669T1 (de) | 2004-01-07 | 2005-01-07 | Verfahren zur anpassung der immunantwort an ein antigen oder immunogen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060035853A1 (de) |
| EP (1) | EP1706140B1 (de) |
| JP (2) | JP4705591B2 (de) |
| AT (1) | ATE512669T1 (de) |
| AU (1) | AU2005204385A1 (de) |
| CA (1) | CA2552004C (de) |
| DK (1) | DK1706140T3 (de) |
| ES (1) | ES2368154T3 (de) |
| WO (1) | WO2005067966A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5646851B2 (ja) * | 2006-11-17 | 2014-12-24 | ジェネトロニクス，インコーポレイティド | エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法 |
| DK2544693T3 (en) * | 2010-03-09 | 2017-12-04 | Biomedical Res Models Inc | Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2 |
| AU2014203873A1 (en) * | 2013-01-07 | 2015-07-30 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
| US9433665B2 (en) * | 2013-01-11 | 2016-09-06 | Cyvax, Inc. | Vaccines for protection from and treatment of alzheimer's disease |
| JP2016513971A (ja) | 2013-03-14 | 2016-05-19 | アルトラバックス インコーポレイテッド | Ｂ型肝炎ウイルスワクチン |
| AU2017423053A1 (en) * | 2017-07-10 | 2020-01-23 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5290563A (en) * | 1989-07-27 | 1994-03-01 | Laboratoire Des Stallergenes | Method for combining a mixture of heterogeneous substances with liposomes |
| US6210663B1 (en) * | 1998-08-20 | 2001-04-03 | The Wistar Institute Of Anatomy And Biology | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting |
| US20030008000A1 (en) * | 2001-03-08 | 2003-01-09 | Wong Jonathan P. | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
| EP1565583A4 (de) * | 2002-10-07 | 2007-11-21 | Novartis Vaccines & Diagnostic | Hiv-vakzine-formulierungen |
| DK2544693T3 (en) * | 2010-03-09 | 2017-12-04 | Biomedical Res Models Inc | Hitherto UNKNOWN ACCESS TO VACCINATION THROUGH MILKHINDER AGAINST HERPES SIMPLEX VIRUS TYPE-2 |
-
2005
- 2005-01-07 DK DK05722399.2T patent/DK1706140T3/da active
- 2005-01-07 US US11/032,487 patent/US20060035853A1/en not_active Abandoned
- 2005-01-07 CA CA2552004A patent/CA2552004C/en active Active
- 2005-01-07 ES ES05722399T patent/ES2368154T3/es active Active
- 2005-01-07 JP JP2006549488A patent/JP4705591B2/ja not_active Expired - Fee Related
- 2005-01-07 AU AU2005204385A patent/AU2005204385A1/en not_active Abandoned
- 2005-01-07 EP EP05722399A patent/EP1706140B1/de not_active Not-in-force
- 2005-01-07 AT AT05722399T patent/ATE512669T1/de not_active IP Right Cessation
- 2005-01-07 WO PCT/US2005/000710 patent/WO2005067966A1/en active Application Filing
-
2010
- 2010-05-26 JP JP2010121028A patent/JP2010180253A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2368154T3 (es) | 2011-11-14 |
| EP1706140B1 (de) | 2011-06-15 |
| DK1706140T3 (da) | 2012-04-16 |
| US20060035853A1 (en) | 2006-02-16 |
| JP2007517897A (ja) | 2007-07-05 |
| CA2552004A1 (en) | 2005-07-28 |
| CA2552004C (en) | 2013-03-05 |
| EP1706140A1 (de) | 2006-10-04 |
| AU2005204385A1 (en) | 2005-07-28 |
| JP2010180253A (ja) | 2010-08-19 |
| JP4705591B2 (ja) | 2011-06-22 |
| WO2005067966A1 (en) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512669T1 (de) | Verfahren zur anpassung der immunantwort an ein antigen oder immunogen | |
| Chang et al. | Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model | |
| Raeven et al. | Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination | |
| WO2007016185A3 (en) | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination | |
| US20090304735A1 (en) | Immunogenic Compositions | |
| Villarreal et al. | Ubiquitin-like molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8 T-cell tumor immunity | |
| EA201590597A1 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
| MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
| SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| Kaur et al. | Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice | |
| Julier et al. | Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses | |
| WO2004043399A3 (en) | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines | |
| EA200900738A1 (ru) | Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 | |
| Jones et al. | Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle | |
| Ligtenberg et al. | NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses | |
| Su et al. | Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models | |
| Bian et al. | Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses | |
| WO2006102901A3 (en) | Immunogenic egfr peptides comprising foreign t cell stimulating epitope | |
| WO2004027036A3 (en) | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine | |
| EA200700017A1 (ru) | Способ усиления иммунного ответа на вакцину | |
| ATE401091T1 (de) | Modifizierte ganzzell-, zellextrakt- und omv- basierte impfstoffe | |
| WO2009094006A3 (en) | Bordetella outer-membrane protein antigens and methods of making and using the same | |
| Abulmagd et al. | Evaluation and characterisation of A and B fragments of Corynebacterium diphtheriae toxin towards recombinant diphtheria vaccine | |
| WO2003063786A3 (en) | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system | |
| CN103705920B (zh) | 胞质多聚腺苷酸化成分结合蛋白4疫苗及其制备和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |